The new new contracts, who’s behind them, and what they mean — delivered to your inbox every week. No credit card, unsubscribe anytime.
Weekly Digest
New new contracts, summarized for you
Straight to Inbox
No login, no app to check — it comes to you
Contract Trends
See who's moving and how much in your market
No credit card required Weekly contract digest
Panacea Biotech Secures $8.9 Million in Additional Vaccine Orders from UNICEF for 2023-2027.
Dec 25, 2025•6 months ago
Contract Type
contract
BiotechnologyHealth Care
Description
Panacea Biotech has extended its supply contract with UNICEF for the WHO pre-qualified pentavalent vaccine, Easyfive-TT, raising the total contract value to $16.8 million for 2026 and adding an award of $3.68 million for 2027. This agreement includes updates with increased values and a fresh award enhancing the company's vaccine order pipeline.
Company Information
Company
Panacea Biotech
About
Panacea Biotech is a biopharmaceutical company specializing in vaccines and biotechnology products. Established in 1994, it has a strong focus on immunization and provides a range of products for public health. The company has been recognized for its commitment to quality and innovation in vaccine development.
Predictive Intelligence
Strategic
ML-powered predictions for Panacea Biotech's next move
